Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep

W. M. Abraham, J. S. Stevenson, M. Eldridge, R. Garrido, L. Nieves

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We examined the effects of nedocromil sodium, a new drug developed for the treatment of reversible obstructive airway disease, on allergen-induced early and late bronchial responses and the development of airway hyperresponsiveness 24 h after challenge in nine allergic sheep. On occasions >2 wk apart the sheep were treated with 1) placebo aerosol (buffered saline) before and 3 h after antigen challenge, 2) an aerosol of nedocromil sodium (1 mg/kg in 3 ml buffered saline) before antigen challenge and placebo 3 h after challenge, and 3) placebo aerosol before and nedocromil sodium aerosol 3 h after challenge. Early and late bronchial responses were determined by measuring specific lung resistance (sR(L)) before and periodically after challenge. Airway responsiveness was assessed by determining from dose-response curves the carbachol concentration (in % wt/vol) that increased sR(L) to 5 cmH2O/s. In the placebo trial, antigen challenge resulted in early and late increases in sRL over a base line of 353 ± 32 and 131 ± 17% (SE), respectively. Both early and late increases in sR(L) were blocked (P < 0.05) when the sheep were pretreated with nedocromil sodium. When nedocromil was given after the early response, the late response was reduced significantly. Eight of nine sheep developed airway hyperresponsiveness 24 h after antigen challenge. In these eight sheep, carbachol concentration before antigen challenge was 2.6 ± 0.3%, 24 h later carbachol concentration was significantly lower (1.8 ± 0.3%). Both nedocromil sodium treatments blocked (P < 0.05) this antigen-induced airway hyperresponsiveness. These findings indicate that nedocromil sodium is effective in the sheep model of allergic bronchoconstriction and therefore may be beneficial in the treatment of reversible obstructive airway disease.

Original languageEnglish
Pages (from-to)1062-1068
Number of pages7
JournalJournal of Applied Physiology
Volume65
Issue number3
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Nedocromil
Allergens
Sheep
Aerosols
Antigens
Carbachol
Placebos
Bronchoconstriction
Therapeutics
Lung

ASJC Scopus subject areas

  • Endocrinology
  • Physiology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Abraham, W. M., Stevenson, J. S., Eldridge, M., Garrido, R., & Nieves, L. (1988). Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep. Journal of Applied Physiology, 65(3), 1062-1068.

Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep. / Abraham, W. M.; Stevenson, J. S.; Eldridge, M.; Garrido, R.; Nieves, L.

In: Journal of Applied Physiology, Vol. 65, No. 3, 01.01.1988, p. 1062-1068.

Research output: Contribution to journalArticle

Abraham, WM, Stevenson, JS, Eldridge, M, Garrido, R & Nieves, L 1988, 'Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep', Journal of Applied Physiology, vol. 65, no. 3, pp. 1062-1068.
Abraham WM, Stevenson JS, Eldridge M, Garrido R, Nieves L. Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep. Journal of Applied Physiology. 1988 Jan 1;65(3):1062-1068.
Abraham, W. M. ; Stevenson, J. S. ; Eldridge, M. ; Garrido, R. ; Nieves, L. / Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep. In: Journal of Applied Physiology. 1988 ; Vol. 65, No. 3. pp. 1062-1068.
@article{880992f41bf84764bafb32c80186adc0,
title = "Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep",
abstract = "We examined the effects of nedocromil sodium, a new drug developed for the treatment of reversible obstructive airway disease, on allergen-induced early and late bronchial responses and the development of airway hyperresponsiveness 24 h after challenge in nine allergic sheep. On occasions >2 wk apart the sheep were treated with 1) placebo aerosol (buffered saline) before and 3 h after antigen challenge, 2) an aerosol of nedocromil sodium (1 mg/kg in 3 ml buffered saline) before antigen challenge and placebo 3 h after challenge, and 3) placebo aerosol before and nedocromil sodium aerosol 3 h after challenge. Early and late bronchial responses were determined by measuring specific lung resistance (sR(L)) before and periodically after challenge. Airway responsiveness was assessed by determining from dose-response curves the carbachol concentration (in {\%} wt/vol) that increased sR(L) to 5 cmH2O/s. In the placebo trial, antigen challenge resulted in early and late increases in sRL over a base line of 353 ± 32 and 131 ± 17{\%} (SE), respectively. Both early and late increases in sR(L) were blocked (P < 0.05) when the sheep were pretreated with nedocromil sodium. When nedocromil was given after the early response, the late response was reduced significantly. Eight of nine sheep developed airway hyperresponsiveness 24 h after antigen challenge. In these eight sheep, carbachol concentration before antigen challenge was 2.6 ± 0.3{\%}, 24 h later carbachol concentration was significantly lower (1.8 ± 0.3{\%}). Both nedocromil sodium treatments blocked (P < 0.05) this antigen-induced airway hyperresponsiveness. These findings indicate that nedocromil sodium is effective in the sheep model of allergic bronchoconstriction and therefore may be beneficial in the treatment of reversible obstructive airway disease.",
author = "Abraham, {W. M.} and Stevenson, {J. S.} and M. Eldridge and R. Garrido and L. Nieves",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "65",
pages = "1062--1068",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Nedocromil sodium in allergen-induced bronchial responses and airway hyperresponsiveness in allergic sheep

AU - Abraham, W. M.

AU - Stevenson, J. S.

AU - Eldridge, M.

AU - Garrido, R.

AU - Nieves, L.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We examined the effects of nedocromil sodium, a new drug developed for the treatment of reversible obstructive airway disease, on allergen-induced early and late bronchial responses and the development of airway hyperresponsiveness 24 h after challenge in nine allergic sheep. On occasions >2 wk apart the sheep were treated with 1) placebo aerosol (buffered saline) before and 3 h after antigen challenge, 2) an aerosol of nedocromil sodium (1 mg/kg in 3 ml buffered saline) before antigen challenge and placebo 3 h after challenge, and 3) placebo aerosol before and nedocromil sodium aerosol 3 h after challenge. Early and late bronchial responses were determined by measuring specific lung resistance (sR(L)) before and periodically after challenge. Airway responsiveness was assessed by determining from dose-response curves the carbachol concentration (in % wt/vol) that increased sR(L) to 5 cmH2O/s. In the placebo trial, antigen challenge resulted in early and late increases in sRL over a base line of 353 ± 32 and 131 ± 17% (SE), respectively. Both early and late increases in sR(L) were blocked (P < 0.05) when the sheep were pretreated with nedocromil sodium. When nedocromil was given after the early response, the late response was reduced significantly. Eight of nine sheep developed airway hyperresponsiveness 24 h after antigen challenge. In these eight sheep, carbachol concentration before antigen challenge was 2.6 ± 0.3%, 24 h later carbachol concentration was significantly lower (1.8 ± 0.3%). Both nedocromil sodium treatments blocked (P < 0.05) this antigen-induced airway hyperresponsiveness. These findings indicate that nedocromil sodium is effective in the sheep model of allergic bronchoconstriction and therefore may be beneficial in the treatment of reversible obstructive airway disease.

AB - We examined the effects of nedocromil sodium, a new drug developed for the treatment of reversible obstructive airway disease, on allergen-induced early and late bronchial responses and the development of airway hyperresponsiveness 24 h after challenge in nine allergic sheep. On occasions >2 wk apart the sheep were treated with 1) placebo aerosol (buffered saline) before and 3 h after antigen challenge, 2) an aerosol of nedocromil sodium (1 mg/kg in 3 ml buffered saline) before antigen challenge and placebo 3 h after challenge, and 3) placebo aerosol before and nedocromil sodium aerosol 3 h after challenge. Early and late bronchial responses were determined by measuring specific lung resistance (sR(L)) before and periodically after challenge. Airway responsiveness was assessed by determining from dose-response curves the carbachol concentration (in % wt/vol) that increased sR(L) to 5 cmH2O/s. In the placebo trial, antigen challenge resulted in early and late increases in sRL over a base line of 353 ± 32 and 131 ± 17% (SE), respectively. Both early and late increases in sR(L) were blocked (P < 0.05) when the sheep were pretreated with nedocromil sodium. When nedocromil was given after the early response, the late response was reduced significantly. Eight of nine sheep developed airway hyperresponsiveness 24 h after antigen challenge. In these eight sheep, carbachol concentration before antigen challenge was 2.6 ± 0.3%, 24 h later carbachol concentration was significantly lower (1.8 ± 0.3%). Both nedocromil sodium treatments blocked (P < 0.05) this antigen-induced airway hyperresponsiveness. These findings indicate that nedocromil sodium is effective in the sheep model of allergic bronchoconstriction and therefore may be beneficial in the treatment of reversible obstructive airway disease.

UR - http://www.scopus.com/inward/record.url?scp=0023792970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023792970&partnerID=8YFLogxK

M3 - Article

C2 - 2846491

AN - SCOPUS:0023792970

VL - 65

SP - 1062

EP - 1068

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 3

ER -